Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 89

Drug Profile

T 89

Alternative Names: Cardiotonic Pills; Compound Danshen Dripping Pills; Danshen Plus; Dantonic Capsule; Salvtonic; T89; Tasly Danshen Plus Capsule

Latest Information Update: 18 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tianjin Tasly Pharmaceutical
  • Developer Tasly Pharmaceutical Group; Tasly Pharmaceuticals, Inc.
  • Class Anti-infectives; Eye disorder therapies; Herbal medicines; Ischaemic heart disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Diabetic retinopathy
  • Phase II Respiration disorders

Most Recent Events

  • 10 Nov 2019 Tasly Pharmaceuticals completes a phase II trial for Respiration disorders (In volunteers) in USA (PO, Capsule) (NCT03552263)
  • 01 Aug 2019 Tasly Pharmaceuticals initiates enrolment in a phase III trial for Angina pectoris in USA (NCT03789552)
  • 28 Dec 2018 Tasly Pharmaceuticals plans a phase III trial for chronic stable Angina pectoris (NCT03789552)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top